Clinical trials: Enterococcus Faecalis Bacteremia, active
Infective Endocarditis (IE)
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis
Enterococci are pathobionts of the human intestinal microbiota: they colonize the gastrointestinal tract as well as the skin, urine, wounds, bile, the oral cavity and endodontic canal, and medical devices (urinary catheters…
- Trial name
- BAC-ENDO (NCT07313865)
- Testing
- Microbiological sampling (swab collection)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Clermont-Ferrand
Enterococcus Faecalis Infection, Blood Stream Infection
Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI)…
- Conditions
- Enterococcus Faecalis Infection, Blood Stream Infection, Gut Microbiomes
- Trial name
- MicroEFfAECT (NCT06833593)
- Where
- 4 sites in Italy
- Volunteers
- 510 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enterococcus Faecalis Bacteremia
Treatment of Enterococcus Faecalis Bacterem
Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis.
- Trial name
- E-faecalis (NCT07299539)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Strasbourg, France